Global Uveitis Market Outlook 2020-2030: Assessment of Competitors, Market, Current Trends & Treatments Along With Upcoming Treatments - ResearchAndMarkets.com

DUBLIN--()--The "Uveitis - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Uveitis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Uveitis market size from 2017 to 2030. The Report also covers current Uveitis treatment practice/algorithm, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Uveitis, Diagnosed Prevalent Population of Uveitis, Gender-specific Diagnosed Prevalent Population of Uveitis, Age-specific Diagnosed Prevalent Population of Uveitis, Type-specific Diagnosed Prevalent Population of Uveitis, Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location, and Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) scenario of uveitis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings

  • As per the analysis, the total Prevalent Population of Uveitis in the 7MM was found to be 897,466 in 2017. The estimates higher prevalence of Uveitis in the United States with 357,791 cases in 2017.
  • Among the European countries, Germany had the maximum prevalent population of Uveitis with 93,260 cases followed by France, which had a prevalent population of 77,331 in 2017.
  • In 2017, it was found that there were 28,111 diagnosed cases of infectious uveitis, and 293,901 cases of non-infectious uveitis in the United States.
  • In 2017, Acute Anterior Uveitis was accounted for 43.00% of the total cases of Uveitis in the United States. Acute anterior noninfectious uveitis includes Grade 0 and 1, and accounts for 98,670 cases in 2017. While, in the same year, 130,795 cases of chronic anterior noninfectious uveitis out of which Grade 2 has 84,581 cases; Grade 3 has 31,528; and Grade 4 has 14,686 cases respectively.
  • Japan accounts second among the 7MM in terms of prevalent cases with 166,478 cases among the 7MM.

Scope of the Report

  • The report covers the descriptive overview of Uveitis, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the Uveitis epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Uveitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Uveitis market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Uveitis market.

Report Highlights

  • The rich emerging pipeline, advancement in the treatment, increasing awareness for the disease, growing population of females in the reproductive age group and availability of better symptom control medications will positively drive the Uveitis market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Uveitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Uveitis. Launch of emerging therapies will significantly impact the Uveitis market.
  • In-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Uveitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Uveitis Pipeline Analysis
  • Uveitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Uveitis Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage

Uveitis Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Uveitis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Companies Mentioned

  • Sirion Therapeutics
  • Novartis
  • Valeant Pharmaceuticals International Inc
  • Aldeyra Therapeutics
  • Santen
  • EyeGate Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/y9m5uy

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900